Overview
- In a phase 3 study of more than 1,500 adults with obesity and type 2 diabetes across 10 countries, the 36 mg dose of orforglipron produced roughly 9.6–10% average weight loss over 72 weeks versus about 2–2.5% with placebo.
- Participants on orforglipron also saw greater reductions in HbA1c, with the safety profile dominated by mild to moderate gastrointestinal effects that were more frequent at higher doses.
- Researchers emphasized simple administration with no restrictions on food or water intake and no cold storage, features intended to improve convenience and adherence relative to injectable GLP-1 therapies.
- Efficacy was lower than top injectable options reported in previous trials, such as tirzepatide’s roughly 20–22% average weight loss over similar durations.
- Study authors and the company say the pill could be manufactured at larger scale and priced below injectables, with potential availability in 2026 if cleared by regulators; a prior trial in people without diabetes reported about 12% weight loss.